Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prometheus forms drug toxicity test deal:

This article was originally published in Clinica

Executive Summary

Prometheus Laboratories has sublicensed from DNA Sciences a patent covering a gene test that identifies people who are at potential risk of drug toxicity. The PROPredictRx TMPT test detects two gene variations that are involved in the production of thiopurine S-methyltransferase (TPMT), an enzyme that is important in metabolising thiopurine drugs used to treat automimmune and inflammatory diseases. Patients with an unrecognised TMPT deficiency and who are treated with thiopurines may suffer potentially fatal drug toxicity, says Prometheus, of San Diego, California.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts